Bishop Named to DTx Pharma Board of Directors
3 May 2022 - - California-based biotechnology company DTx Pharma, Inc has appointed Kathie M. Bishop, PhD, to its board of directors, the company said.

Coming into the role, Dr. Bishop brings more than two decade's worth of experience in translational research and drug development, with a focus on novel therapeutics for the treatment of neurological and rare diseases.

She is currently senior vice president, chief scientific officer and Head of Rare Disease at Acadia Pharmaceuticals.

As a scientist-turned-executive, Dr. Bishop has previously led research and development as CSO at LocanaBio, Otonomy, and Tioga Pharmaceuticals and held leadership roles at Ionis and Ceregene.

In relation to the appointment, Dr. Bishop also brings intimate knowledge of RNA therapeutics to the role.

Previously, she served as VP, Clinical Development at Ionis Pharmaceuticals where she spearheaded the translation and development of multiple programs in the neurology franchise including Spinraza (nusinersen).

Dr. Bishop earned her Ph.D. from the University of Alberta and conducted post-doctoral work at the Salk Institute for Biological Studies in La Jolla.

DTx Pharma is a private clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics.

The company's proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body.

In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types.

To advance the FALCON platform toward and into clinical development, DTx has raised more than USD 100m in combined investment from several of the world's leading healthcare investors including RA Capital Management and Access biotechnology, pharmaceutical companies such as Eli Lilly and company, the National Institute of Health, and research foundations such as the CMT Research Foundation (CMTRF).